{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:09:16Z","timestamp":1791889756722,"version":"4.3.4"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T00:00:00Z","timestamp":1466467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T00:00:00Z","timestamp":1466467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50AG016574"],"award-info":[{"award-number":["P50AG016574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1AG051504"],"award-info":[{"award-number":["RF1AG051504"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG027924"],"award-info":[{"award-number":["R01AG027924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG035355"],"award-info":[{"award-number":["R01AG035355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG046205"],"award-info":[{"award-number":["R01AG046205"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01NS074969"],"award-info":[{"award-number":["P01NS074969"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40263-016-0361-4","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T16:26:58Z","timestamp":1466612818000},"page":"773-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Apolipoprotein E as a Therapeutic Target in Alzheimer\u2019s Disease: A Review of Basic Research and Clinical Evidence"],"prefix":"10.1007","volume":"30","author":[{"given":"Yu","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan M.","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kanekiyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,21]]},"reference":[{"issue":"5","key":"361_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/gim.2015.117","volume":"18","author":"C Van Cauwenberghe","year":"2016","unstructured":"Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421\u201330.","journal-title":"Genet Med"},{"issue":"1","key":"361_CR2","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"10","key":"361_CR3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet. 2009;41(10):1088\u201393.","journal-title":"Nat Genet"},{"issue":"10","key":"361_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet. 2009;41(10):1094\u20139.","journal-title":"Nat Genet"},{"issue":"4","key":"361_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/hmg\/3.4.569","volume":"3","author":"MC Chartier-Harlin","year":"1994","unstructured":"Chartier-Harlin MC, Parfitt M, Legrain S, Perez-Tur J, Brousseau T, Evans A, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer\u2019s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet. 1994;3(4):569\u201374.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"361_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat Genet. 2011;43(5):429\u201335.","journal-title":"Nat Genet"},{"issue":"5","key":"361_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/ng.801","volume":"43","author":"AC Naj","year":"2011","unstructured":"Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer\u2019s disease. Nat Genet. 2011;43(5):436\u201341.","journal-title":"Nat Genet"},{"issue":"2","key":"361_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer\u2019s disease. N Engl J Med. 2013;368(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"361_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med. 2013;368(2):107\u201316.","journal-title":"N Engl J Med"},{"issue":"12","key":"361_CR10","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45(12):1452\u20138.","journal-title":"Nat Genet"},{"issue":"4","key":"361_CR11","doi-asserted-by":"publisher","first-page":"968-e1","DOI":"10.1016\/j.cell.2013.10.037","volume":"155","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Bras J, Hardy J. SnapShot: genetics of Alzheimer\u2019s disease. Cell. 2013;155(4):968-e1.","journal-title":"Cell"},{"issue":"1","key":"361_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"CM Karch","year":"2015","unstructured":"Karch CM, Goate AM. Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43\u201351.","journal-title":"Biol Psychiatry"},{"issue":"18","key":"361_CR13","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/hmg\/ddm171","volume":"16","author":"O Belbin","year":"2007","unstructured":"Belbin O, Dunn JL, Ling Y, Morgan L, Chappell S, Beaumont H, et al. Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer\u2019s disease. Hum Mol Genet. 2007;16(18):2199\u2013208.","journal-title":"Hum Mol Genet"},{"key":"361_CR14","doi-asserted-by":"crossref","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997;278(16):1349\u201356.","DOI":"10.1001\/jama.1997.03550160069041"},{"issue":"2","key":"361_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0021-9150(93)90129-I","volume":"98","author":"MI Kamboh","year":"1993","unstructured":"Kamboh MI, Aston CE, Ferrell RE, Hamman RF. Impact of apolipoprotein E polymorphism in determining interindividual variation in total cholesterol and low density lipoprotein cholesterol in Hispanics and non-Hispanic whites. Atherosclerosis. 1993;98(2):201\u201311.","journal-title":"Atherosclerosis."},{"issue":"5123","key":"361_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133.","journal-title":"Science"},{"key":"361_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2377-8-9","volume":"8","author":"SB Sando","year":"2008","unstructured":"Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, et al. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer\u2019s disease; a case control study from central Norway. BMC Neurol. 2008;8:9.","journal-title":"BMC Neurol."},{"issue":"1","key":"361_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0304-3940(94)11213-3","volume":"185","author":"M Lehtovirta","year":"1995","unstructured":"Lehtovirta M, Helisalmi S, Mannermaa A, Soininen H, Koivisto K, Ryynanen M, et al. Apolipoprotein E polymorphism and Alzheimer\u2019s disease in eastern Finland. Neurosci Lett. 1995;185(1):13\u20135.","journal-title":"Neurosci Lett"},{"issue":"8873","key":"361_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0140-6736(93)91705-Q","volume":"342","author":"J Poirier","year":"1993","unstructured":"Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer\u2019s disease. Lancet. 1993;342(8873):697\u20139.","journal-title":"Lancet"},{"issue":"5","key":"361_CR20","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/ana.24628","volume":"79","author":"M Shinohara","year":"2016","unstructured":"Shinohara M, Kanekiyo T, Yang LY, Linthicum D, Shinohara M, Fu Y, et al. APOE2 eases cognitive decline during aging: clinical and preclinical evaluations. Ann Neurol. 2016;79(5):758\u201374.","journal-title":"Ann Neurol"},{"issue":"4","key":"361_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","volume":"81","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer\u2019s disease: accidental encounters or partners? Neuron. 2014;81(4):740\u201354.","journal-title":"Neuron"},{"issue":"2","key":"361_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106\u201318.","journal-title":"Nat Rev Neurol."},{"issue":"Suppl","key":"361_CR23","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1194\/jlr.R800058-JLR200","volume":"50","author":"GS Getz","year":"2009","unstructured":"Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res. 2009;50(Suppl):S156\u201361.","journal-title":"J Lipid Res"},{"issue":"3","key":"361_CR24","doi-asserted-by":"publisher","first-page":"a006312","DOI":"10.1101\/cshperspect.a006312","volume":"2","author":"DM Holtzman","year":"2012","unstructured":"Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312.","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"Suppl","key":"361_CR25","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1194\/jlr.R800069-JLR200","volume":"50","author":"RW Mahley","year":"2009","unstructured":"Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer\u2019s disease to AIDS. J Lipid Res. 2009;50(Suppl):S183\u20138.","journal-title":"J Lipid Res"},{"issue":"21","key":"361_CR26","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1021\/jm3008618","volume":"55","author":"RW Mahley","year":"2012","unstructured":"Mahley RW, Huang Y. Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. J Med Chem. 2012;55(21):8997\u20139008.","journal-title":"J Med Chem"},{"issue":"29","key":"361_CR27","doi-asserted-by":"crossref","first-page":"14352","DOI":"10.1016\/S0021-9258(18)47945-8","volume":"262","author":"RE Pitas","year":"1987","unstructured":"Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J Biol Chem. 1987;262(29):14352\u201360.","journal-title":"J Biol Chem"},{"issue":"8","key":"361_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tibs.2006.06.008","volume":"31","author":"DM Hatters","year":"2006","unstructured":"Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006;31(8):445\u201354.","journal-title":"Trends Biochem Sci"},{"issue":"35","key":"361_CR29","doi-asserted-by":"crossref","first-page":"22358","DOI":"10.1016\/S0021-9258(17)31797-0","volume":"269","author":"LM Dong","year":"1994","unstructured":"Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, et al. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem. 1994;269(35):22358\u201365.","journal-title":"J Biol Chem"},{"issue":"6","key":"361_CR30","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1046\/j.1471-4159.2003.01788.x","volume":"85","author":"J Saura","year":"2003","unstructured":"Saura J, Petegnief V, Wu X, Liang Y, Paul SM. Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. J Neurochem. 2003;85(6):1455\u201367.","journal-title":"J Neurochem"},{"issue":"1315","key":"361_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.brainres.2009.12.039","volume":"22","author":"IB Bruinsma","year":"2010","unstructured":"Bruinsma IB, Wilhelmus MM, Kox M, Veerhuis R, de Waal RM, Verbeek MM. Apolipoprotein E protects cultured pericytes and astrocytes from D-Abeta(1-40)-mediated cell death. Brain Res. 2010;22(1315):169\u201380.","journal-title":"Brain Res"},{"key":"361_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1749-6632.2000.tb06368.x","volume":"903","author":"MM Verbeek","year":"2000","unstructured":"Verbeek MM, Van Nostrand WE, Otte-Holler I, Wesseling P, De Waal RM. Amyloid-beta-induced degeneration of human brain pericytes is dependent on the apolipoprotein E genotype. Ann N Y Acad Sci. 2000;903:187\u201399.","journal-title":"Ann N Y Acad Sci"},{"issue":"22","key":"361_CR33","doi-asserted-by":"publisher","first-page":"14208","DOI":"10.1074\/jbc.M114.625251","volume":"290","author":"CS Casey","year":"2015","unstructured":"Casey CS, Atagi Y, Yamazaki Y, Shinohara M, Tachibana M, Fu Y, et al. Apolipoprotein E inhibits cerebrovascular pericyte mobility through a RhoA protein-mediated pathway. J Biol Chem. 2015;290(22):14208\u201317.","journal-title":"J Biol Chem"},{"issue":"5","key":"361_CR34","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1046\/j.1471-4159.1998.70052070.x","volume":"70","author":"MJ LaDu","year":"1998","unstructured":"LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70(5):2070\u201381.","journal-title":"J Neurochem"},{"issue":"5","key":"361_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrn2620","volume":"10","author":"G Bu","year":"2009","unstructured":"Bu G. Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333\u201344.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"361_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/scientificamerican0506-72","volume":"294","author":"MS Wolfe","year":"2006","unstructured":"Wolfe MS. Shutting down Alzheimer\u2019s. Sci Am. 2006;294(5):72\u20139.","journal-title":"Sci Am"},{"issue":"5580","key":"361_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science"},{"issue":"2","key":"361_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","volume":"6","author":"CA Lemere","year":"2010","unstructured":"Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6(2):108\u201319.","journal-title":"Nat Rev Neurol."},{"issue":"43","key":"361_CR39","doi-asserted-by":"publisher","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","volume":"32","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci. 2012;32(43):15181\u201392.","journal-title":"J Neurosci"},{"key":"361_CR40","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/brain\/aws127","volume":"135","author":"RM Koffie","year":"2012","unstructured":"Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, et al. Apolipoprotein E4 effects in Alzheimer\u2019s disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain. 2012;135:2155\u201368.","journal-title":"Brain."},{"issue":"5","key":"361_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00401-010-0666-1","volume":"119","author":"DZ Christensen","year":"2010","unstructured":"Christensen DZ, Schneider-Axmann T, Lucassen PJ, Bayer TA, Wirths O. Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. Acta Neuropathol. 2010;119(5):555\u201366.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"361_CR42","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.21696","volume":"65","author":"E Kok","year":"2009","unstructured":"Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009;65(6):650\u20137.","journal-title":"Ann Neurol."},{"issue":"19","key":"361_CR43","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1056\/NEJM199511093331902","volume":"333","author":"T Polvikoski","year":"1995","unstructured":"Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333(19):1242\u20137.","journal-title":"N Engl J Med"},{"issue":"20","key":"361_CR44","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1073\/pnas.90.20.9649","volume":"90","author":"DE Schmechel","year":"1993","unstructured":"Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci. 1993;90(20):9649\u201353.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"361_CR45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp-2013-306485","volume":"85","author":"K Rannikmae","year":"2014","unstructured":"Rannikmae K, Kalaria RN, Greenberg SM, Chui HC, Schmitt FA, Samarasekera N, et al. APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85(3):300\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"361_CR46","doi-asserted-by":"crossref","unstructured":"Shinohara M, Murray ME, Frank RD, DeTure M, Yamazaki Y, Tachibana M, et al. Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer\u2019s disease. Acta Neuropathol. 2016;1\u201310.","DOI":"10.1007\/s00401-016-1580-y"},{"issue":"6","key":"361_CR47","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/ana.410410607","volume":"41","author":"JA Nicoll","year":"1997","unstructured":"Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997;41(6):716\u201321.","journal-title":"Ann Neurol."},{"issue":"6","key":"361_CR48","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ana.22134","volume":"68","author":"A Biffi","year":"2010","unstructured":"Biffi A, Sonni A, Anderson CD, Kissela B, Jagiella JM, Schmidt H, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010;68(6):934\u201343.","journal-title":"Ann Neurol."},{"issue":"4","key":"361_CR49","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.neuroscience.2003.10.011","volume":"124","author":"PM Sullivan","year":"2004","unstructured":"Sullivan PM, Mace BE, Maeda N, Schmechel DE. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience. 2004;124(4):725\u201333.","journal-title":"Neuroscience"},{"issue":"21","key":"361_CR50","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1523\/JNEUROSCI.0887-09.2009","volume":"29","author":"KR Bales","year":"2009","unstructured":"Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci. 2009;29(21):6771\u20139.","journal-title":"J Neurosci"},{"key":"361_CR51","doi-asserted-by":"crossref","unstructured":"Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med. 2011;3(89):89ra57.","DOI":"10.1126\/scitranslmed.3002156"},{"issue":"50","key":"361_CR52","doi-asserted-by":"publisher","first-page":"41774","DOI":"10.1074\/jbc.M112.407957","volume":"287","author":"KL Youmans","year":"2012","unstructured":"Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287(50):41774\u201386.","journal-title":"J Biol Chem"},{"issue":"3","key":"361_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/ng1197-263","volume":"17","author":"KR Bales","year":"1997","unstructured":"Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17(3):263\u20134.","journal-title":"Nat Genet"},{"issue":"1","key":"361_CR54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/exnr.1998.6860","volume":"153","author":"E Ghebremedhin","year":"1998","unstructured":"Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer\u2019s disease-related neurofibrillary changes. Exp Neurol. 1998;153(1):152\u20135.","journal-title":"Exp Neurol"},{"issue":"3","key":"361_CR55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/0306-4522(95)00331-C","volume":"69","author":"Z Nagy","year":"1995","unstructured":"Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer\u2019s disease. Neuroscience. 1995;69(3):757\u201361.","journal-title":"Neuroscience"},{"issue":"3","key":"361_CR56","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/0306-4522(94)00596-W","volume":"66","author":"TG Ohm","year":"1995","unstructured":"Ohm TG, Kirca M, Bohl J, Scharnagl H, Gross W, Marz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience. 1995;66(3):583\u20137.","journal-title":"Neuroscience"},{"issue":"9","key":"361_CR57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM199602293340913","volume":"334","author":"Y Itoh","year":"1996","unstructured":"Itoh Y, Yamada M. Apolipoprotein E and the neuropathology of dementia. N Engl J Med. 1996;334(9):599\u2013600.","journal-title":"N Engl J Med"},{"issue":"4","key":"361_CR58","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/jnnp.61.4.352","volume":"61","author":"M Landen","year":"1996","unstructured":"Landen M, Thorsell A, Wallin A, Blennow K. The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 1996;61(4):352\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"361_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0304-3940(94)12126-B","volume":"201","author":"CM Morris","year":"1995","unstructured":"Morris CM, Benjamin R, Leake A, McArthur FK, Candy JM, Ince PG, et al. Effect of apolipoprotein E genotype on Alzheimer\u2019s disease neuropathology in a cohort of elderly Norwegians. Neurosci Lett. 1995;201(1):45\u20137.","journal-title":"Neurosci Lett"},{"issue":"1","key":"361_CR60","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1212\/WNL.47.1.190","volume":"47","author":"JM Olichney","year":"1996","unstructured":"Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer\u2019s disease and Lewy body variant. Neurology. 1996;47(1):190\u20136.","journal-title":"Neurology."},{"issue":"1","key":"361_CR61","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/0169-328X(94)00233-5","volume":"29","author":"F Oyama","year":"1995","unstructured":"Oyama F, Shimada H, Oyama R, Ihara Y. Apolipoprotein E genotype, Alzheimer\u2019s pathologies and related gene expression in the aged population. Brain Res Mol Brain Res. 1995;29(1):92\u20138.","journal-title":"Brain Res Mol Brain Res"},{"issue":"43","key":"361_CR62","doi-asserted-by":"publisher","first-page":"44795","DOI":"10.1074\/jbc.M408127200","volume":"279","author":"FM Harris","year":"2004","unstructured":"Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J Biol Chem. 2004;279(43):44795\u2013801.","journal-title":"J Biol Chem"},{"key":"361_CR63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1326-8-16","volume":"8","author":"O Liraz","year":"2013","unstructured":"Liraz O, Boehm-Cagan A, Michaelson DM. ApoE4 induces Abeta42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol Neurodegener. 2013;8:16.","journal-title":"Mol Neurodegener."},{"issue":"5","key":"361_CR64","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/NEN.0b013e31828e24ab","volume":"72","author":"RE Bennett","year":"2013","unstructured":"Bennett RE, Esparza TJ, Lewis HA, Kim E, Mac Donald CL, Sullivan PM, et al. Human apolipoprotein E4 worsens acute axonal pathology but not amyloid-beta immunoreactivity after traumatic brain injury in 3xTG-AD mice. J Neuropathol Exp Neurol. 2013;72(5):396\u2013403.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"19","key":"361_CR65","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1523\/JNEUROSCI.5476-05.2006","volume":"26","author":"Q Xu","year":"2006","unstructured":"Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006;26(19):4985\u201394.","journal-title":"J Neurosci"},{"issue":"19","key":"361_CR66","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.1434398100","volume":"100","author":"FM Harris","year":"2003","unstructured":"Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer\u2019s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci. 2003;100(19):10966\u201371.","journal-title":"Proc Natl Acad Sci."},{"issue":"5","key":"361_CR67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364.","journal-title":"Ann Neurol."},{"key":"361_CR68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13024-015-0013-z","volume":"10","author":"M Marttinen","year":"2015","unstructured":"Marttinen M, Kurkinen KM, Soininen H, Haapasalo A, Hiltunen M. Synaptic dysfunction and septin protein family members in neurodegenerative diseases. Mol Neurodegener. 2015;10:16.","journal-title":"Mol Neurodegener."},{"key":"361_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Abeta-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:48.","journal-title":"Mol Neurodegener."},{"key":"361_CR70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, Brinkmalm G, Honer WG, Frolich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:53.","journal-title":"Mol Neurodegener."},{"key":"361_CR71","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1750-1326-9-41","volume":"9","author":"KA Price","year":"2014","unstructured":"Price KA, Varghese M, Sowa A, Yuk F, Brautigam H, Ehrlich ME, et al. Altered synaptic structure in the hippocampus in a mouse model of Alzheimer\u2019s disease with soluble amyloid-beta oligomers and no plaque pathology. Mol Neurodegener. 2014;9:41.","journal-title":"Mol Neurodegener."},{"issue":"5","key":"361_CR72","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.neurobiolaging.2006.03.016","volume":"28","author":"B Schonheit","year":"2007","unstructured":"Schonheit B, Glockner F, Ohm TG. Apolipoprotein E polymorphism and dendritic shape in hippocampal interneurons. Neurobiol Aging. 2007;28(5):677\u201386.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"361_CR73","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1523\/JNEUROSCI.17-02-00516.1997","volume":"17","author":"T Arendt","year":"1997","unstructured":"Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer\u2019s disease carrying apolipoprotein epsilon 4 allele. J Neurosci. 1997;17(2):516\u201329.","journal-title":"J Neurosci"},{"issue":"2","key":"361_CR74","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.nbd.2004.10.013","volume":"18","author":"C Wang","year":"2005","unstructured":"Wang C, Wilson WA, Moore SD, Mace BE, Maeda N, Schmechel DE, et al. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis. 2005;18(2):390\u20138.","journal-title":"Neurobiol Dis"},{"issue":"48","key":"361_CR75","doi-asserted-by":"publisher","first-page":"15317","DOI":"10.1523\/JNEUROSCI.4026-09.2009","volume":"29","author":"SB Dumanis","year":"2009","unstructured":"Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29(48):15317\u201322.","journal-title":"J Neurosci"},{"issue":"2","key":"361_CR76","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.neuroscience.2003.08.007","volume":"122","author":"Y Ji","year":"2003","unstructured":"Ji Y, Gong Y, Gan W, Beach T, Holtzman DM, Wisniewski T. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer\u2019s disease patients. Neuroscience. 2003;122(2):305\u201315.","journal-title":"Neuroscience"},{"key":"361_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-015-0002-2","volume":"10","author":"DS Liu","year":"2015","unstructured":"Liu DS, Pan XD, Zhang J, Shen H, Collins NC, Cole AM, et al. APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener. 2015;10:7.","journal-title":"Mol Neurodegener."},{"issue":"3","key":"361_CR78","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10787-012-0130-z","volume":"20","author":"GJ Broussard","year":"2012","unstructured":"Broussard GJ, Mytar J, Li RC, Klapstein GJ. The role of inflammatory processes in Alzheimer\u2019s disease. Inflammopharmacology. 2012;20(3):109\u201326.","journal-title":"Inflammopharmacology"},{"key":"361_CR79","doi-asserted-by":"crossref","unstructured":"Bales KR, Du Y, Holtzman D, Cordell B, Paul SM. Neuroinflammation and Alzheimer\u2019s disease: critical roles for cytokine\/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging. 2000;21(3):427\u201332 (discussion 51\u20133).","DOI":"10.1016\/S0197-4580(00)00143-3"},{"key":"361_CR80","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13024-015-0048-1","volume":"10","author":"M Malik","year":"2015","unstructured":"Malik M, Parikh I, Vasquez JB, Smith C, Tai L, Bu G, et al. Genetics ignite focus on microglial inflammation in Alzheimer\u2019s disease. Mol Neurodegener. 2015;10:52.","journal-title":"Mol Neurodegener."},{"key":"361_CR81","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1750-1326-9-33","volume":"9","author":"V Landel","year":"2014","unstructured":"Landel V, Baranger K, Virard I, Loriod B, Khrestchatisky M, Rivera S, et al. Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:33.","journal-title":"Mol Neurodegener."},{"issue":"6","key":"361_CR82","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/archneurol.2012.277","volume":"69","author":"JM Ringman","year":"2012","unstructured":"Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, et al. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Arch Neurol. 2012;69(6):757\u201364.","journal-title":"Arch Neurol"},{"issue":"49","key":"361_CR83","doi-asserted-by":"publisher","first-page":"48529","DOI":"10.1074\/jbc.M306923200","volume":"278","author":"JR Lynch","year":"2003","unstructured":"Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem. 2003;278(49):48529\u201333.","journal-title":"J Biol Chem"},{"issue":"9","key":"361_CR84","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.neurobiolaging.2007.11.014","volume":"30","author":"MP Vitek","year":"2009","unstructured":"Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009;30(9):1350\u201360.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"361_CR85","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/glia.22289","volume":"60","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia. 2012;60(4):559\u201369.","journal-title":"Glia."},{"issue":"5","key":"361_CR86","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00401-015-1522-0","volume":"131","author":"S Love","year":"2016","unstructured":"Love S, Miners JS. Cerebrovascular disease in ageing and Alzheimer\u2019s disease. Acta Neuropathol. 2016;131(5):645\u201358.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"361_CR87","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamaneurol.2014.754","volume":"71","author":"MI Kester","year":"2014","unstructured":"Kester MI, Goos JDC, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, et al. Associations between cerebral small-vessel disease and alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. Jama Neurol. 2014;71(7):855\u201362.","journal-title":"Jama Neurol."},{"issue":"1","key":"361_CR88","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/jcbfm.2015.44","volume":"36","author":"MR Halliday","year":"2016","unstructured":"Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2016;36(1):216\u201327.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"361_CR89","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1365-2990.2003.00457.x","volume":"29","author":"K Chalmers","year":"2003","unstructured":"Chalmers K, Wilcock GK, Love S. APOE epsilon 4 influences the pathological phenotype of Alzheimer\u2019s disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol. 2003;29(3):231\u20138.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"361_CR90","first-page":"19","volume":"3","author":"S Love","year":"2014","unstructured":"Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K, et al. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis. 2014;3(1):19\u201332.","journal-title":"Am J Neurodegener Dis."},{"issue":"11","key":"361_CR91","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1523\/JNEUROSCI.5170-04.2005","volume":"25","author":"JD Fryer","year":"2005","unstructured":"Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci. 2005;25(11):2803\u201310.","journal-title":"J Neurosci"},{"issue":"1","key":"361_CR92","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/jcbfm.2014.172","volume":"35","author":"W Alata","year":"2015","unstructured":"Alata W, Ye Y, St-Amour I, Vandal M, Calon F. Human apolipoprotein E varepsilon4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J Cereb Blood Flow Metab. 2015;35(1):86\u201394.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7399","key":"361_CR93","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature11087","volume":"485","author":"RD Bell","year":"2012","unstructured":"Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):512\u20136.","journal-title":"Nature"},{"issue":"2","key":"361_CR94","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","volume":"88","author":"N Bien-Ly","year":"2015","unstructured":"Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, et al. Lack of widespread BBB disruption in Alzheimer\u2019s disease models: focus on therapeutic antibodies. Neuron. 2015;88(2):289\u201397.","journal-title":"Neuron"},{"issue":"360","key":"361_CR95","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jns.2015.12.004","volume":"15","author":"P Talwar","year":"2016","unstructured":"Talwar P, Sinha J, Grover S, Agarwal R, Kushwaha S, Srivastava MV, et al. Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. J Neurol Sci. 2016;15(360):179\u201387.","journal-title":"J Neurol Sci"},{"issue":"5","key":"361_CR96","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","volume":"127","author":"E Martinez-Morillo","year":"2014","unstructured":"Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients and controls. Acta Neuropathol. 2014;127(5):633\u201343.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"361_CR97","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1074\/mcp.M112.018861","volume":"11","author":"R Simon","year":"2012","unstructured":"Simon R, Girod M, Fonbonne C, Salvador A, Clement Y, Lanteri P, et al. Total ApoE and ApoE4 isoform assays in an Alzheimer\u2019s disease case-control study by targeted mass spectrometry (n\u00a0=\u00a0669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics. 2012;11(11):1389\u2013403.","journal-title":"Mol Cell Proteomics"},{"key":"361_CR98","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-015-0059-y","volume":"10","author":"WE Heywood","year":"2015","unstructured":"Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 2015;10:64.","journal-title":"Mol Neurodegener."},{"issue":"21","key":"361_CR99","doi-asserted-by":"publisher","first-page":"7293","DOI":"10.1523\/JNEUROSCI.5198-13.2014","volume":"34","author":"A Boehm-Cagan","year":"2014","unstructured":"Boehm-Cagan A, Michaelson DM. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. J Neurosci. 2014;34(21):7293\u2013301.","journal-title":"J Neurosci"},{"issue":"6075","key":"361_CR100","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1126\/science.1217697","volume":"335","author":"PE Cramer","year":"2012","unstructured":"Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012;335(6075):1503\u20136.","journal-title":"Science"},{"key":"361_CR101","doi-asserted-by":"crossref","unstructured":"Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, et al. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science. 2013;340(6135):924-d.","DOI":"10.1126\/science.1234089"},{"key":"361_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2015.12.003","volume":"277","author":"M Tachibana","year":"2016","unstructured":"Tachibana M, Shinohara M, Yamazaki Y, Liu CC, Rogers J, Bu G, et al. Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. Exp Neurol. 2016;277:1\u20139.","journal-title":"Exp Neurol"},{"key":"361_CR103","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1750-1326-8-18","volume":"8","author":"KD LaClair","year":"2013","unstructured":"LaClair KD, Manaye KF, Lee DL, Allard JS, Savonenko AV, Troncoso JC, et al. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP\/PS1 mice. Mol Neurodegener. 2013;8:18.","journal-title":"Mol Neurodegener."},{"issue":"44","key":"361_CR104","doi-asserted-by":"publisher","first-page":"30538","DOI":"10.1074\/jbc.M114.600833","volume":"289","author":"LM Tai","year":"2014","unstructured":"Tai LM, Koster KP, Luo J, Lee SH, Wang YT, Collins NC, et al. Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem. 2014;289(44):30538\u201355.","journal-title":"J Biol Chem"},{"key":"361_CR105","doi-asserted-by":"crossref","unstructured":"Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, et al. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science. 2013;340(6135):924-e.","DOI":"10.1126\/science.1233937"},{"key":"361_CR106","doi-asserted-by":"crossref","unstructured":"Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, et al. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science. 2013;340(6135):924-f.","DOI":"10.1126\/science.1235505"},{"issue":"3","key":"361_CR107","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1471-4159.2006.03925.x","volume":"98","author":"MP Burns","year":"2006","unstructured":"Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, et al. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J Neurochem. 2006;98(3):792\u2013800.","journal-title":"J Neurochem"},{"issue":"44","key":"361_CR108","doi-asserted-by":"publisher","first-page":"34144","DOI":"10.1074\/jbc.M110.108100","volume":"285","author":"JJ Donkin","year":"2010","unstructured":"Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein\/presenilin 1 mice. J Biol Chem. 2010;285(44):34144\u201354.","journal-title":"J Biol Chem"},{"issue":"5","key":"361_CR109","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Q Jiang","year":"2008","unstructured":"Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58(5):681\u201393.","journal-title":"Neuron"},{"issue":"6","key":"361_CR110","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1074\/jbc.M411420200","volume":"280","author":"RP Koldamova","year":"2005","unstructured":"Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer\u2019s disease. J Biol Chem. 2005;280(6):4079\u201388.","journal-title":"J Biol Chem"},{"issue":"24","key":"361_CR111","doi-asserted-by":"publisher","first-page":"9173","DOI":"10.1523\/JNEUROSCI.1000-15.2015","volume":"35","author":"BT Casali","year":"2015","unstructured":"Casali BT, Corona AW, Mariani MM, Karlo JC, Ghosal K, Landreth GE. Omega-3 fatty acids augment the actions of nuclear receptor agonists in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2015;35(24):9173\u201381.","journal-title":"J Neurosci"},{"issue":"4","key":"361_CR112","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.mcn.2007.01.011","volume":"34","author":"DR Riddell","year":"2007","unstructured":"Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer\u2019s disease. Mol Cell Neurosci. 2007;34(4):621\u20138.","journal-title":"Mol Cell Neurosci"},{"issue":"7","key":"361_CR113","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.neurobiolaging.2009.07.005","volume":"32","author":"T Vanmierlo","year":"2011","unstructured":"Vanmierlo T, Rutten K, Dederen J, Bloks VW, van Vark-van der Zee LC, Kuipers F, et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol Aging. 2011;32(7):1262\u201372.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"361_CR114","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/npp.2010.32","volume":"35","author":"L Escribano","year":"2010","unstructured":"Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, et al. Rosiglitazone rescues memory impairment in Alzheimer\u2019s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology. 2010;35(7):1593\u2013604.","journal-title":"Neuropsychopharmacology."},{"issue":"35","key":"361_CR115","doi-asserted-by":"publisher","first-page":"21591","DOI":"10.1074\/jbc.M115.652008","volume":"290","author":"R Skerrett","year":"2015","unstructured":"Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE. Combined liver X receptor\/peroxisome proliferator-activated receptor gamma agonist treatment reduces amyloid beta levels and improves behavior in amyloid precursor protein\/presenilin 1 mice. J Biol Chem. 2015;290(35):21591\u2013602.","journal-title":"J Biol Chem"},{"issue":"6","key":"361_CR116","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrd4280","volume":"13","author":"C Hong","year":"2014","unstructured":"Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13(6):433\u201344.","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"361_CR117","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","volume":"12","author":"N Mehta","year":"2012","unstructured":"Mehta N, Wayne AS, Kim YH, Hale GA, Alvarado CS, Myskowski P, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk. 2012;12(1):20\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"361_CR118","doi-asserted-by":"crossref","unstructured":"Gregoriou S, Rigopoulos D, Stamou C, Nikolaou V, Kontochristopoulos G. Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas. J Cutan Med Surg. 2013;17(1):52\u20134.","DOI":"10.2310\/7750.2012.12022"},{"issue":"1","key":"361_CR119","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/bjd.12042","volume":"168","author":"JJ Scarisbrick","year":"2013","unstructured":"Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168(1):192\u2013200.","journal-title":"Br J Dermatol"},{"issue":"3","key":"361_CR120","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2340\/00015555-1359","volume":"92","author":"L Vakeva","year":"2012","unstructured":"Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012;92(3):258\u201363.","journal-title":"Acta Derm Venereol"},{"key":"361_CR121","doi-asserted-by":"crossref","unstructured":"Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d. Science. 2013;340(6135):924-c.","DOI":"10.1126\/science.1235809"},{"issue":"1","key":"361_CR122","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","volume":"8","author":"JL Cummings","year":"2016","unstructured":"Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8(1):4.","journal-title":"Alzheimers Res Ther"},{"issue":"5548","key":"361_CR123","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1126\/science.294.5548.1866","volume":"294","author":"A Chawla","year":"2001","unstructured":"Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294(5548):1866\u201370.","journal-title":"Science"},{"issue":"Suppl 2","key":"361_CR124","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1038\/sj.cdd.4401533","volume":"11","author":"A Szanto","year":"2004","unstructured":"Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ. 2004;11(Suppl 2):S126\u201343.","journal-title":"Cell Death Differ"},{"issue":"20","key":"361_CR125","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1021\/jm050285w","volume":"48","author":"F Sussman","year":"2005","unstructured":"Sussman F, de Lera AR. Ligand recognition by RAR and RXR receptors: binding and selectivity. J Med Chem. 2005;48(20):6212\u20139.","journal-title":"J Med Chem"},{"issue":"1","key":"361_CR126","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","volume":"157","author":"RM Evans","year":"2014","unstructured":"Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang. Cell. 2014;157(1):255\u201366.","journal-title":"Cell"},{"issue":"16","key":"361_CR127","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1074\/jbc.M113.526095","volume":"289","author":"J Zhao","year":"2014","unstructured":"Zhao J, Fu Y, Liu CC, Shinohara M, Nielsen HM, Dong Q, et al. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor\/retinoic acid receptor pathway. J Biol Chem. 2014;289(16):11282\u201392.","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"361_CR128","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbrc.2015.10.132","volume":"468","author":"C Roman","year":"2015","unstructured":"Roman C, Fuior EV, Trusca VG, Kardassis D, Simionescu M, Gafencu AV. Thyroid hormones upregulate apolipoprotein E gene expression in astrocytes. Biochem Biophys Res Commun. 2015;468(1\u20132):190\u20135.","journal-title":"Biochem Biophys Res Commun."},{"issue":"14","key":"361_CR129","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1523\/JNEUROSCI.0033-12.2012","volume":"32","author":"N Bien-Ly","year":"2012","unstructured":"Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci. 2012;32(14):4803\u201311.","journal-title":"J Neurosci"},{"issue":"49","key":"361_CR130","doi-asserted-by":"publisher","first-page":"18007","DOI":"10.1523\/JNEUROSCI.3773-11.2011","volume":"31","author":"J Kim","year":"2011","unstructured":"Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci. 2011;31(49):18007\u201312.","journal-title":"J Neurosci"},{"issue":"21","key":"361_CR131","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","volume":"34","author":"F Liao","year":"2014","unstructured":"Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, et al. Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis. J Neurosci. 2014;34(21):7281\u201392.","journal-title":"J Neurosci"},{"issue":"12","key":"361_CR132","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1084\/jem.20121274","volume":"209","author":"J Kim","year":"2012","unstructured":"Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Stewart FR, et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med. 2012;209(12):2149\u201356.","journal-title":"J Exp Med"},{"issue":"10","key":"361_CR133","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaneurol.2014.2011","volume":"71","author":"AC Mak","year":"2014","unstructured":"Mak AC, Pullinger CR, Tang LF, Wong JS, Deo RC, Schwarz JM, et al. Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71(10):1228\u201336.","journal-title":"JAMA Neurol."},{"issue":"6","key":"361_CR134","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jalz.2014.06.015","volume":"10","author":"DM Michaelson","year":"2014","unstructured":"Michaelson DM. APOE epsilon4: the most prevalent yet understudied risk factor for Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(6):861\u20138.","journal-title":"Alzheimers Dement."},{"issue":"1","key":"361_CR135","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1385\/JMN:24:1:073","volume":"24","author":"MA Marques","year":"2004","unstructured":"Marques MA, Owens PA, Crutcher KA. Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain. J Mol Neurosci. 2004;24(1):73\u201380.","journal-title":"J Mol Neurosci"},{"issue":"15","key":"361_CR136","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1523\/JNEUROSCI.17-15-05678.1997","volume":"17","author":"M Tolar","year":"1997","unstructured":"Tolar M, Marques MA, Harmony JA, Crutcher KA. Neurotoxicity of the 22\u00a0kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci. 1997;17(15):5678\u201386.","journal-title":"J Neurosci"},{"key":"361_CR137","doi-asserted-by":"crossref","unstructured":"Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci. 2005;102(51):18694\u20139.","DOI":"10.1073\/pnas.0508254102"},{"issue":"2","key":"361_CR138","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neurobiolaging.2009.02.006","volume":"32","author":"DA Elliott","year":"2011","unstructured":"Elliott DA, Tsoi K, Holinkova S, Chan SL, Kim WS, Halliday GM, et al. Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging. 2011;32(2):257\u201371.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"361_CR139","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1073\/pnas.1018381108","volume":"108","author":"N Bien-Ly","year":"2011","unstructured":"Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Wang C, Huang Y. C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice. Proc Natl Acad Sci. 2011;108(10):4236\u201341.","journal-title":"Proc Natl Acad Sci."},{"issue":"5","key":"361_CR140","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jmb.2006.06.080","volume":"361","author":"DM Hatters","year":"2006","unstructured":"Hatters DM, Zhong N, Rutenber E, Weisgraber KH. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol. 2006;361(5):932\u201344.","journal-title":"J Mol Biol"},{"issue":"1","key":"361_CR141","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2010.12.003","volume":"130","author":"DO Osei-Hwedieh","year":"2011","unstructured":"Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther. 2011;130(1):83\u201391.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"361_CR142","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000341299","volume":"12","author":"K Ghosal","year":"2013","unstructured":"Ghosal K, Stathopoulos A, Thomas D, Phenis D, Vitek MP, Pimplikar SW. The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer\u2019s disease-like pathological features. Neurodegener Dis. 2013;12(1):51\u20138.","journal-title":"Neurodegener Dis."},{"issue":"1\u20134","key":"361_CR143","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000334914","volume":"10","author":"MP Vitek","year":"2012","unstructured":"Vitek MP, Christensen DJ, Wilcock D, Davis J, Van Nostrand WE, Li FQ, et al. APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer\u2019s disease transgenics. Neurodegener Dis. 2012;10(1\u20134):122\u20136.","journal-title":"Neurodegener Dis."},{"key":"361_CR144","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1326-5-16","volume":"5","author":"SS Minami","year":"2010","unstructured":"Minami SS, Cordova A, Cirrito JR, Tesoriero JA, Babus LW, Davis GC, et al. ApoE mimetic peptide decreases Abeta production in vitro and in vivo. Mol Neurodegener. 2010;5:16.","journal-title":"Mol Neurodegener."},{"issue":"2","key":"361_CR145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JAD-122377","volume":"36","author":"SP Handattu","year":"2013","unstructured":"Handattu SP, Monroe CE, Nayyar G, Palgunachari MN, Kadish I, van Groen T, et al. In vivo and in vitro effects of an apolipoprotein e mimetic peptide on amyloid-beta pathology. J Alzheimers Dis. 2013;36(2):335\u201347.","journal-title":"J Alzheimers Dis"},{"key":"361_CR146","doi-asserted-by":"crossref","unstructured":"Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013;5(212):212ra161.","DOI":"10.1126\/scitranslmed.3007000"},{"key":"361_CR147","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13024-015-0001-3","volume":"10","author":"J Hu","year":"2015","unstructured":"Hu J, Liu CC, Chen XF, Zhang YW, Xu H, Bu G. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Abeta metabolism in apoE4-targeted replacement mice. Mol Neurodegener. 2015;10:6.","journal-title":"Mol Neurodegener."},{"issue":"4","key":"361_CR148","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1073\/pnas.0409072102","volume":"102","author":"JC Dodart","year":"2005","unstructured":"Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci. 2005;102(4):1211\u20136.","journal-title":"Proc Natl Acad Sci."},{"issue":"3","key":"361_CR149","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jalz.2008.01.006","volume":"4","author":"N Zhong","year":"2008","unstructured":"Zhong N, Scearce-Levie K, Ramaswamy G, Weisgraber KH. Apolipoprotein E4 domain interaction: synaptic and cognitive deficits in mice. Alzheimers Dement. 2008;4(3):179\u201392.","journal-title":"Alzheimers Dement."},{"issue":"7","key":"361_CR150","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1074\/jbc.M110.151084","volume":"286","author":"HK Chen","year":"2011","unstructured":"Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, et al. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem. 2011;286(7):5215\u201321.","journal-title":"J Biol Chem"},{"issue":"19","key":"361_CR151","doi-asserted-by":"publisher","first-page":"17217","DOI":"10.1074\/jbc.M110.217380","volume":"286","author":"J Brodbeck","year":"2011","unstructured":"Brodbeck J, McGuire J, Liu Z, Meyer-Franke A, Balestra ME, Jeong DE, et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J Biol Chem. 2011;286(19):17217\u201326.","journal-title":"J Biol Chem"},{"issue":"4","key":"361_CR152","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nbt.3155","volume":"33","author":"LE Dow","year":"2015","unstructured":"Dow LE, Fisher J, O\u2019Rourke KP, Muley A, Kastenhuber ER, Livshits G, et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol. 2015;33(4):390\u20134.","journal-title":"Nat Biotechnol"},{"issue":"6271","key":"361_CR153","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351(6271):407\u201311.","journal-title":"Science"},{"issue":"6271","key":"361_CR154","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351(6271):403\u20137.","journal-title":"Science"},{"issue":"6271","key":"361_CR155","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351(6271):400\u20133.","journal-title":"Science"},{"issue":"1","key":"361_CR156","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJMp1506446","volume":"373","author":"ES Lander","year":"2015","unstructured":"Lander ES. Brave New Genome. N Engl J Med. 2015;373(1):5\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"361_CR157","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.plipres.2010.09.001","volume":"50","author":"PS Hauser","year":"2011","unstructured":"Hauser PS, Narayanaswami V, Ryan RO. Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res. 2011;50(1):62\u201374.","journal-title":"Prog Lipid Res"},{"issue":"39","key":"361_CR158","doi-asserted-by":"publisher","first-page":"40987","DOI":"10.1074\/jbc.M407963200","volume":"279","author":"SE Wahrle","year":"2004","unstructured":"Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279(39):40987\u201393.","journal-title":"J Biol Chem"},{"issue":"52","key":"361_CR159","doi-asserted-by":"publisher","first-page":"43236","DOI":"10.1074\/jbc.M508780200","volume":"280","author":"SE Wahrle","year":"2005","unstructured":"Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280(52):43236\u201342.","journal-title":"J Biol Chem"},{"issue":"2","key":"361_CR160","first-page":"671","volume":"118","author":"SE Wahrle","year":"2008","unstructured":"Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118(2):671\u201382.","journal-title":"J Clin Invest."},{"issue":"8","key":"361_CR161","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/jamaneurol.2013.396","volume":"70","author":"AJ Hanson","year":"2013","unstructured":"Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. Jama Neurol. 2013;70(8):972\u201380.","journal-title":"Jama Neurol."},{"issue":"8","key":"361_CR162","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","volume":"288","author":"LM Tai","year":"2013","unstructured":"Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E\/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013;288(8):5914\u201326.","journal-title":"J Biol Chem"},{"issue":"8","key":"361_CR163","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.bbalip.2010.02.007","volume":"1801","author":"JE Vance","year":"2010","unstructured":"Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta. 2010;1801(8):806\u201318.","journal-title":"Biochim Biophys Acta"},{"key":"361_CR164","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1326-9-2","volume":"9","author":"LM Tai","year":"2014","unstructured":"Tai LM, Mehra S, Shete V, Estus S, Rebeck GW, Bu G, et al. Soluble apoE\/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener. 2014;9:2.","journal-title":"Mol Neurodegener."},{"issue":"7","key":"361_CR165","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1073\/pnas.0913828107","volume":"107","author":"EY Bryleva","year":"2010","unstructured":"Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci. 2010;107(7):3081\u20136.","journal-title":"Proc Natl Acad Sci."},{"issue":"1","key":"361_CR166","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.90926.2008","volume":"297","author":"TY Chang","year":"2009","unstructured":"Chang TY, Li BL, Chang CC, Urano Y. Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009;297(1):E1\u20139.","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"43","key":"361_CR167","doi-asserted-by":"publisher","first-page":"14484","DOI":"10.1523\/JNEUROSCI.2567-14.2014","volume":"34","author":"Y Shibuya","year":"2014","unstructured":"Shibuya Y, Chang CC, Huang LH, Bryleva EY, Chang TY. Inhibiting ACAT1\/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Abeta1-42 clearance. J Neurosci. 2014;34(43):14484\u2013501.","journal-title":"J Neurosci."},{"issue":"2","key":"361_CR168","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jama.2009.1988","volume":"303","author":"AE Sanders","year":"2010","unstructured":"Sanders AE, Wang C, Katz M, Derby CA, Barzilai N, Ozelius L, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA. 2010;303(2):150\u20138.","journal-title":"JAMA"},{"issue":"19","key":"361_CR169","doi-asserted-by":"publisher","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"PB Verghese","year":"2013","unstructured":"Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE\/Abeta association in physiological conditions. Proc Natl Acad Sci. 2013;110(19):E1807\u201316.","journal-title":"Proc Natl Acad Sci."},{"issue":"1","key":"361_CR170","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer\u2019s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163\u20136.","journal-title":"Brain Res"},{"issue":"5","key":"361_CR171","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.ajpath.2013.01.034","volume":"182","author":"MA Kuszczyk","year":"2013","unstructured":"Kuszczyk MA, Sanchez S, Pankiewicz J, Kim J, Duszczyk M, Guridi M, et al. Blocking the interaction between apolipoprotein E and Abeta reduces intraneuronal accumulation of Abeta and inhibits synaptic degeneration. Am J Pathol. 2013;182(5):1750\u201368.","journal-title":"Am J Pathol"},{"issue":"49","key":"361_CR172","doi-asserted-by":"publisher","first-page":"18787","DOI":"10.1073\/pnas.0604011103","volume":"103","author":"MJ Sadowski","year":"2006","unstructured":"Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, et al. Blocking the apolipoprotein E\/amyloid-beta interaction as a potential therapeutic approach for Alzheimer\u2019s disease. Proc Natl Acad Sci. 2006;103(49):18787\u201392.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"361_CR173","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/jnc.12484","volume":"128","author":"S Liu","year":"2014","unstructured":"Liu S, Breitbart A, Sun Y, Mehta PD, Boutajangout A, Scholtzova H, et al. Blocking the apolipoprotein E\/amyloid beta interaction in triple transgenic mice ameliorates Alzheimer\u2019s disease related amyloid beta and tau pathology. J Neurochem. 2014;128(4):577\u201391.","journal-title":"J Neurochem"},{"key":"361_CR174","first-page":"75","volume":"2","author":"JE Pankiewicz","year":"2014","unstructured":"Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, et al. Blocking the apoE\/Abeta interaction ameliorates Abeta-related pathology in APOE epsilon2 and epsilon4 targeted replacement Alzheimer model mice. Acta Neuropathol Commun. 2014;2:75.","journal-title":"Acta Neuropathol Commun."},{"issue":"4","key":"361_CR175","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.npep.2010.03.001","volume":"44","author":"J Hao","year":"2010","unstructured":"Hao J, Zhang W, Zhang P, Liu R, Liu L, Lei G, et al. Abeta20-29 peptide blocking apoE\/Abeta interaction reduces full-length Abeta42\/40 fibril formation and cytotoxicity in vitro. Neuropeptides. 2010;44(4):305\u201313.","journal-title":"Neuropeptides."},{"issue":"5","key":"361_CR176","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1523\/JNEUROSCI.5491-10.2011","volume":"31","author":"T Kanekiyo","year":"2011","unstructured":"Kanekiyo T, Zhang J, Liu Q, Liu CC, Zhang L, Bu G. Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci. 2011;31(5):1644\u201351.","journal-title":"J Neurosci"},{"issue":"50","key":"361_CR177","doi-asserted-by":"publisher","first-page":"17068","DOI":"10.1523\/JNEUROSCI.4067-10.2010","volume":"30","author":"Q Liu","year":"2010","unstructured":"Liu Q, Trotter J, Zhang J, Peters MM, Cheng H, Bao J, et al. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci. 2010;30(50):17068\u201378.","journal-title":"J Neurosci"},{"issue":"5","key":"361_CR178","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","volume":"64","author":"J Kim","year":"2009","unstructured":"Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64(5):632\u201344.","journal-title":"Neuron"},{"issue":"49","key":"361_CR179","doi-asserted-by":"publisher","first-page":"19276","DOI":"10.1523\/JNEUROSCI.3487-13.2013","volume":"33","author":"T Kanekiyo","year":"2013","unstructured":"Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, et al. Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J Neurosci. 2013;33(49):19276\u201383.","journal-title":"J Neurosci"},{"issue":"29","key":"361_CR180","doi-asserted-by":"publisher","first-page":"22091","DOI":"10.1074\/jbc.M110.102277","volume":"285","author":"M Shinohara","year":"2010","unstructured":"Shinohara M, Sato N, Kurinami H, Takeuchi D, Takeda S, Shimamura M, et al. Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J Biol Chem. 2010;285(29):22091\u2013102.","journal-title":"J Biol Chem"},{"issue":"1","key":"361_CR181","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-2012-120319","volume":"31","author":"H Qosa","year":"2012","unstructured":"Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer\u2019s disease. J Alzheimers Dis. 2012;31(1):151\u201365.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"361_CR182","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.neuron.2014.08.005","volume":"83","author":"C Lane-Donovan","year":"2014","unstructured":"Lane-Donovan C, Philips GT, Herz J. More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron. 2014;83(4):771\u201387.","journal-title":"Neuron"},{"issue":"26","key":"361_CR183","doi-asserted-by":"publisher","first-page":"12011","DOI":"10.1073\/pnas.0914984107","volume":"107","author":"Y Chen","year":"2010","unstructured":"Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci. 2010;107(26):12011\u20136.","journal-title":"Proc Natl Acad Sci."},{"issue":"6","key":"361_CR184","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2174\/1567205010666131119232444","volume":"11","author":"M Gilat-Frenkel","year":"2014","unstructured":"Gilat-Frenkel M, Boehm-Cagan A, Liraz O, Xian X, Herz J, Michaelson DM. Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo. Curr Alzheimer Res. 2014;11(6):549\u201357.","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"361_CR185","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1001\/jamaneurol.2013.3841","volume":"70","author":"MR Halliday","year":"2013","unstructured":"Halliday MR, Pomara N, Sagare AP, Mack WJ, Frangione B, Zlokovic BV. Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. Jama Neurol. 2013;70(9):1198\u2013200.","journal-title":"Jama Neurol."},{"issue":"2","key":"361_CR186","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuron.2015.10.008","volume":"88","author":"JD Ulrich","year":"2015","unstructured":"Ulrich JD, Huynh TP, Holtzman DM. Re-evaluation of the blood-brain barrier in the presence of Alzheimer\u2019s disease pathology. Neuron. 2015;88(2):237\u20139.","journal-title":"Neuron"},{"issue":"1","key":"361_CR187","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/1381612820666141020164222","volume":"21","author":"AJ Hanson","year":"2015","unstructured":"Hanson AJ, Craft S, Banks WA. The APOE genotype: modification of therapeutic responses in Alzheimer\u2019s disease. Curr Pharm Des. 2015;21(1):114\u201320.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"361_CR188","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):322\u201333.","journal-title":"N Engl J Med"},{"issue":"7","key":"361_CR189","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","volume":"27","author":"J Freiherr","year":"2013","unstructured":"Freiherr J, Hallschmid M, Frey WH 2nd, Brunner YF, Chapman CD, Holscher C, et al. Intranasal insulin as a treatment for Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27(7):505\u201314.","journal-title":"CNS Drugs."},{"key":"361_CR190","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1749-6632.2000.tb06371.x","volume":"903","author":"S Craft","year":"2000","unstructured":"Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer\u2019s disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci. 2000;903:222\u20138.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"361_CR191","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3233\/JAD-122308","volume":"35","author":"A Claxton","year":"2013","unstructured":"Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer\u2019s disease. J Alzheimers Dis. 2013;35(4):789\u201397.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"361_CR192","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","volume":"13","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323\u201331.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"361_CR193","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.wnl.0000284596.95156.48","volume":"70","author":"CA Szekely","year":"2008","unstructured":"Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology. 2008;70(1):17\u201324.","journal-title":"Neurology."},{"issue":"4","key":"361_CR194","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ana.24135","volume":"75","author":"A Altmann","year":"2014","unstructured":"Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563\u201373.","journal-title":"Ann Neurol."},{"issue":"7","key":"361_CR195","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neurobiolaging.2010.10.007","volume":"33","author":"JH Kang","year":"2012","unstructured":"Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging. 2012;33(7):1129\u201337.","journal-title":"Neurobiol Aging."},{"issue":"5","key":"361_CR196","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.tins.2014.03.001","volume":"37","author":"DA Raichlen","year":"2014","unstructured":"Raichlen DA, Alexander GE. Exercise, APOE genotype, and the evolution of the human lifespan. Trends Neurosci. 2014;37(5):247\u201355.","journal-title":"Trends Neurosci"},{"issue":"3","key":"361_CR197","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jalz.2013.03.003","volume":"10","author":"RE Kennedy","year":"2014","unstructured":"Kennedy RE, Cutter GR, Schneider LS. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(3):349\u201359.","journal-title":"Alzheimers Dement."},{"issue":"5","key":"361_CR198","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci. 1993;90(5):1977\u201381.","journal-title":"Proc Natl Acad Sci."},{"issue":"2","key":"361_CR199","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016;34(2):204\u20139.","journal-title":"Nat Biotechnol"},{"key":"361_CR200","doi-asserted-by":"publisher","first-page":"16026","DOI":"10.1038\/mtm.2016.26","volume":"3","author":"AM Rosario","year":"2016","unstructured":"Rosario AM, Cruz PE, Ceballos-Diaz C, Strickland MR, Siemienski Z, Pardo M, et al. Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol Therapy Methods Clin Dev. 2016;3:16026.","journal-title":"Mol Therapy Methods Clin Dev."},{"issue":"4","key":"361_CR201","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1073\/pnas.1401965111","volume":"112","author":"K Takao","year":"2015","unstructured":"Takao K, Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci. 2015;112(4):1167\u201372.","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"361_CR202","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1073\/pnas.1222878110","volume":"110","author":"J Seok","year":"2013","unstructured":"Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci. 2013;110(9):3507\u201312.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"361_CR203","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731\u20138.","journal-title":"J Immunol."},{"key":"361_CR204","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1326-9-60","volume":"9","author":"C Marquer","year":"2014","unstructured":"Marquer C, Laine J, Dauphinot L, Hanbouch L, Lemercier-Neuillet C, Pierrot N, et al. Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer\u2019s disease early phenotypes. Mol Neurodegener. 2014;9:60.","journal-title":"Mol Neurodegener."},{"issue":"4","key":"361_CR205","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.stem.2013.01.009","volume":"12","author":"T Kondo","year":"2013","unstructured":"Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer\u2019s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell. 2013;12(4):487\u201396.","journal-title":"Cell Stem Cell"},{"issue":"7384","key":"361_CR206","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10821","volume":"482","author":"MA Israel","year":"2012","unstructured":"Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and familial Alzheimer\u2019s disease using induced pluripotent stem cells. Nature. 2012;482(7384):216\u201320.","journal-title":"Nature"},{"issue":"7526","key":"361_CR207","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nature13800","volume":"515","author":"SH Choi","year":"2014","unstructured":"Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D\u2019Avanzo C, et al. A three-dimensional human neural cell culture model of Alzheimer\u2019s disease. Nature. 2014;515(7526):274\u20138.","journal-title":"Nature"},{"issue":"12","key":"361_CR208","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","volume":"9","author":"E Giacobini","year":"2013","unstructured":"Giacobini E, Gold G. Alzheimer disease therapy\u2013moving from amyloid-beta to tau. Nat Rev Neurol. 2013;9(12):677\u201386.","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"361_CR209","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/ana.20694","volume":"59","author":"O Gureje","year":"2006","unstructured":"Gureje O, Ogunniyi A, Baiyewu O, Price B, Unverzagt FW, Evans RM, et al. APOE epsilon4 is not associated with Alzheimer\u2019s disease in elderly Nigerians. Ann Neurol. 2006;59(1):182\u20135.","journal-title":"Ann Neurol."},{"issue":"1","key":"361_CR210","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10072-011-0663-8","volume":"33","author":"AA Rassas","year":"2012","unstructured":"Rassas AA, Mrabet Khiari H, Hadj Fredj S, Sahnoun S, Batti H, Zakraoui NO, et al. High APOE epsilon 4 allele frequencies associated with Alzheimer disease in a Tunisian population. Neurol Sci. 2012;33(1):33\u20137.","journal-title":"Neurol Sci."},{"issue":"1","key":"361_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2004.10.073","volume":"375","author":"AV Raygani","year":"2005","unstructured":"Raygani AV, Zahrai M, Doosti M, Javadi E, Rezaei M, Pourmotabbed T. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. Neurosci Lett. 2005;375(1):1\u20136.","journal-title":"Neurosci Lett."},{"issue":"3","key":"361_CR212","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0304-3940(99)00867-8","volume":"277","author":"KW Kim","year":"1999","unstructured":"Kim KW, Jhoo JH, Lee KU, Lee DY, Lee JH, Youn JY, et al. Association between apolipoprotein E polymorphism and Alzheimer\u2019s disease in Koreans. Neurosci Lett. 1999;277(3):145\u20138.","journal-title":"Neurosci Lett"},{"issue":"1","key":"361_CR213","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng1934","volume":"39","author":"L Bertram","year":"2007","unstructured":"Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17\u201323.","journal-title":"Nat Genet"},{"issue":"2","key":"361_CR214","first-page":"439","volume":"60","author":"H Bickeboller","year":"1997","unstructured":"Bickeboller H, Campion D, Brice A, Amouyel P, Hannequin D, Didierjean O, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet. 1997;60(2):439\u201346.","journal-title":"Am J Hum Genet"},{"key":"361_CR215","doi-asserted-by":"crossref","unstructured":"Bahia VS, Kok F, Marie SN, Shinjo SO, Caramelli P, Nitrini R. Polymorphisms of APOE and LRP genes in Brazilian individuals with Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(1):61\u20135.","DOI":"10.1097\/WAD.0b013e31815a9da7"},{"issue":"1","key":"361_CR216","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000026195","volume":"18","author":"P Quiroga","year":"1999","unstructured":"Quiroga P, Calvo C, Albala C, Urquidi J, Santos JL, Perez H, et al. Apolipoprotein E polymorphism in elderly Chilean people with Alzheimer\u2019s disease. Neuroepidemiology. 1999;18(1):48\u201352.","journal-title":"Neuroepidemiology."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0361-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0361-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T01:22:32Z","timestamp":1656724952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0361-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,21]]},"references-count":216,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0361-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,21]]},"assertion":[{"value":"21 June 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by Grants from the National Institutes of Health (NIH) (P50AG016574, RF1AG051504, R01AG027924, R01AG035355, R01AG046205, and P01NS074969 to G.B.); American Heart Association (to T.K.); Japan Society for the Promotion of Science (JSPS) and Mochida Memorial Foundation for Medical & Pharmaceutical Research (to Y.Y.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yu Yamazaki, Meghan M. Painter, Guojun Bu and Takahisa Kanekiyo declare that they have no conflict of interest in relation to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}